XRAY
Undervalued by 230.5% based on the discounted cash flow analysis.
Market cap | $2.63 Billion |
---|---|
Enterprise Value | $4.92 Billion |
Dividend Yield | $0.64 (4.85%) |
Earnings per Share | $-4.48 |
Beta | 0.97 |
Outstanding Shares | 199,300,000 |
Return on Equity | - |
---|---|
Return on Assets | - |
Return on Invested Capital | - |
P/E Ratio | -2.77 |
---|---|
PEG | -0.27 |
Price to Sales | 0.73 |
Price to Book Ratio | 1.47 |
Enterprise Value to Revenue | 1.34 |
Enterprise Value to EBIT | -9.51 |
Enterprise Value to Net Income | -6 |
Total Debt to Enterprise | 0.54 |
Debt to Equity | 1.35 |
No data
No data